Structural and kinetic analysis of drug resistant mutants of HIV-1 protease

European Journal of Biochemistry

Volumn 263, Issue 1, 1999, Pages 238-244

  Mahalingam, Bhuvaneshwari ^a   Louis, John M ^b   Reed, Charles C ^a   Adomat, Jill M ^a   Krouse, Jennifer ^a   Wang, Yuan Fang ^a   Harrison, Robert W ^a   Weber, Irene T ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Aspartic protease; Crystal structure; Drug resistance; HIV 1

Indexed keywords

ANTIRETROVIRUS AGENT; ASPARTIC PROTEINASE; PROTEINASE; RNA DIRECTED DNA POLYMERASE; UREA;

ANTIBIOTIC RESISTANCE; ARTICLE; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME SPECIFICITY; ENZYME STABILITY; ENZYME STRUCTURE; ENZYMOLOGY; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROPHOBICITY; NONHUMAN; PRIORITY JOURNAL; VIROGENESIS; VIRUS MUTANT; VIRUS MUTATION; VIRUS RESISTANCE;

EID: 1942534433     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-1327.1999.00514.x     Document Type: Article

References (36)

1. 1. Oroszlan, S. & Luftig, R.B. (1990) Retroviral proteinases. Curr. Topics Microbiol. Immunol. 157, 153-185.
2. 2. DeBouck, C. (1992) The HIV-1 protease as a therapeutic target for AIDS. AIDS Res. Hum. Retroviruses 8, 153-164.
3. 3. Rose, J.R., Babe, L.M. & Craik, C.S. (1995) Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity. J. Virol. 69, 2751-2758.
4. 4. Kaplan, A.M., Zack, J.A., Knigge, M., Paul, D.A., Kempf, D.J., Norbeck, D.W. & Swanstrom, R. (1993) Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J. Virol. 67, 4050-4055.
5. 5. Karacostas, V., Wolffe, E.J., Nagashima, K., Gonda, M.A. & Moss, B. (1993) Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. Virology 193, 661-671.
6. 6. Louis, J.M., Nashed, N.T., Parris, K.D., Rimmel, A.R. & Jerina, D.M. (1994) Kinetics and mechanism of autoprocessing of human immunodeficiency virus type 1 protease from an analog of the Gag-Pol polyprotein. Proc. Natl Acad. Sci. USA 91, 7970-7974.
7. 7. Tessmer, U. & Krausslich, H.G. (1998) Cleavage of human immunodeficiency virus type 1 proteinase from the N-terminally adjacent p6* protein is essential for efficient Gag polyprotein processing and viral infectivity. J. Virol. 72, 3459-3463.
8. 8. Pettit, S.C., Moody, M.D., Wehbie, R.S., Kaplan, A.H., Nantermet, P.V., Klein, C.A. & Swanstrom, R. (1994) The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions. J. Virol. 68, 8017-8027.
9. 9. Weber, I.T., Wu, J., Adomat, J., Harrison, R.W., Kimmel, A.R., Wondrak, E.M. & Louis, J.M. (1997) Crystallographic analysis of H1V-1 protease with an analog of the conserved CA-p2 substrate: Interactions with frequently occurring Glu at P2′ position of substrate. Eur. J. Biochem. 249, 523-530.
10. 10. Wu, J., Adomat, J.M., Ridky, T.W., Louis, J.M., Leis, J., Harrison, R.W. & Weber, I.T. (1998) Structural basis for specificity of retroviral proteases. Biochemistry 37, 4518-1526.
11. 11. Serio, D., Rizvi, T.A., Cartas, M., Kalyanaraman, V.S., Weber, I.T., Koprowski, H. & Srinivasan, A. (1997) Development of a novel anti-HIV-1 agent from within: effect of chimeric Vpr containing protease cleavage site residues on virus replication. Proc. Natl Acad. Sci. USA 94, 3346-3351.
12. 12. Misumi, S., Kudo, A., Azuma, R., Tomonaga, M., Furuishi, K. & Shoji, S. (1997) The p2gag peptide, AEAMSQVTNTATIM, processed from HIV-1 Pr55gag was found to be a suicide inhibitor of HIV-1 protease. Biochem. Biophys. Res. Commun. 241, 275-280.
13. 13. Condra, J.H., Schleif, W.A., Blahy, O.M., Gabryelski, L.J., Graham, D.J., Quintero, J.C., Rhodes, A., Robbins, H.L., Roth, E., Shivaprakash, M., Titus, D., Yang, T., Teppler, H., Squires, K.E., Deutsch, P.J. & Emini, E.A. (1995) In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569-571.
14. 14. Schinazi, R.F., Larder, B.A. & Mellors, J.W. (1997) Mutations in retroviral genes associated with drug resistance. Int. Antiviral News 5, 129-142.
15. 15. Shafer, R.W., Winters, M.A., Palmer, S., Merigan & T.C. (1998) Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann. Intern. Med. 128, 906-911.
16. 16. Gulnik, S.V., Suvorov, L.I., Liu, B., Yu, B., Anderson, B., Mitsuya, H. & Erickson, J.W. (1995) Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34, 9282-9287.
17. 17. Pazhanisamy, S., Stuver, C.M., Cullinan, A.B., Margolin, N., Rao, B.G. & Livingston, D.J. (1996) Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants. J. Biol. Chem. 271, 17979-17985.
18. 18. Maschera, B., Darby, G., Palu, G., Wright, L.L., Tisdale, M., Myers, R., Blair, E.D. & Furfune, E.S. (1996) Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex. J. Biol. Chem. 271, 33231-33235.
19. 19. Ho, D.D., Toyoshima, T., Mo, H., Kempf, D.J., Norbeck, D., Chen, C.-M., Wideburg, N.E., Burt, S.K., Erickson, J.W. & Singh, M.K. (1994) Characterization of Human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J. Virol. 68, 2016-2020.
20. 20. Weber, I.T. (1990) Comparison of the crystal structures and intersubunit interactions of human immunodeficiency and Rous sarcoma virus proteases. J. Biol. Chem. 265, 10492-10496.
21. 21. Wondrak, E.M. & Louis, J.M. (1996) Influence of flanking sequences on the dimer stability of human immunodeficiency virus type 1 protease. Biochemistry 35, 12957-12962.
22. 22. Grinde, B., Cameron, C.E., Leis, L., Weber, I.T., Wlodawer, A., Burstein, H., Bizub, D. & Skalka, A.M. (1992) Mutations that alter the activity of the Rous sarcoma virus protease. J. Biol. Chem. 267, 9481-9490.
23. 23. Maibaum, J. & Rich, D. (1988) Inhibition of porcine pepsin by two substrate analogues containing statine. The effect of histidine at the P2 subsite on the inhibition of aspartic proteinases. J. Med. Chem. 31, 625-629.
24. 24. Jandu, S.K., Ray, S.R., Brooks, L. & Leatherbarrow, R.J. (1990) Role of arginine 67 in the stabilisation of chymotrypsin inhibitor 2: examination of amide proton exchange rates and denaturation thermodynamics of an engineered protein. Biochemistry 29, 6265-6269.
25. 25. Brunger, A.T., Kuriyan, J. & Karplus, M. (1987) Crystallographic R factor refinement by molecular dynamics. Science 235, 458-460.
26. 26. Jones, T.A. (1985) Diffraction methods for biological macromolecules. Interactive computer graphics: FRODO. Methods Enzymol 115, 157-171.
27. 27. Jones, S. & Thornton, J.M. (1996) Principles of protein-protein interaction. Proc. Natl Acad. Sci. USA 93, 13-20.
28. 28. Wallace, A.C., Laskowski, R.A. & Thornton, J.M. (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Prot. Eng. 8, 127-143.
29. 29. Manchester, M., Everitt, L., Loeb, D.D., Hytchinson, C.A. & Swanstrom, R. (1994) Identification of temperature-sensitive mutants of the human immunodeficiency virus type 1 protease through saturation mutagenesis. J. Biol. Chem. 269, 7689-7695.
30. 30. Loeb, D., Swanstrom, R., Everitt, L., Manchester, M., Stamper, S. & Hutchinson, C. (1989) Complete mutagenesis of the HIV-1 protease. Nature 340, 397-400.
31. 31. Tozser, J., Yin, F.H., Cheng, Y.-S.E., Bagossi, P., Weber, I.T., Harrison, R.W. & Oroszlan, S. (1997) Activity of tethered HIV-1 proteases containing mutations in the flap region of one subunit. Eur. J. Biochem. 244, 235-241.
32. 32. Baldwin, W.T., Bhat, T.N., Liu, B., Pattabiraman, N. & Erickson, J.W. (1995) Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase. Nat. Struct. Biol. 2, 244-249.
33. 33. Hong, L., Treharne, A., Hartsuck, J.A., Foundling, S. & Tang, J. (1996) Crystal structures of complexes of a peptidic inhibitor with wild-type and two mutant HIV-1 proteases. Biochemistry 35, 10627-10633.
34. 34. Zennou, V., Mammano, F., Paulous, S., Mathez, D. & Claval, F. (1998) Loss of viral fitness associated wifh multiple Gag and Gag-Pol processing defects in human immunodeficiency vims type 1 variants selected for resistance to protease inhibitors in vivo. J. Virol. 72, 3300-3306.
35. 35. Ala, P.J., Huston, E.E., Klabe, R.M., McCabe, D.D., Duke, J.L., Rizzo, C.J., Korant, B.D., DeLoskey, R.J., Lam, P.Y., Hodge, C.N. & Chang, C.H. (1997) Molecular basis of HIV-1 protease drug resistance: structural analysis of mutant proteases complexed with cyclic urea inhibitors. Biochemistry 36, 1573-1580.
36. 36. Kraulis, P.J. (1991) MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Cryst. 24, 946-950.